Tiziana Life Sciences announces dosing of additional patients in MS Expanded Access Program
Portfolio Pulse from
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has expanded its dosing of patients in the MS Expanded Access Program, adding four new patients to the trial for its investigational therapy, intranasal foralumab.
February 18, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tiziana Life Sciences has increased the number of patients in its MS Expanded Access Program, potentially indicating progress and interest in its investigational therapy, intranasal foralumab.
The expansion of the patient cohort in the MS program suggests progress in the development of Tiziana's investigational therapy, which could be seen positively by investors as it indicates potential efficacy and interest in the treatment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100